211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome
Conditions: Acute Lymphoblastic Leukemia in Remission; Acute Myeloid Leukemia in Remission; Chronic Myelomonocytic Leukemia; Myeloproliferative Neoplasm, Unclassifiable Interventions: Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10; Drug: Fludarabine; Drug: Cyclophosphamide; Radiation: Total-Body Irradiation; Procedure: Peripheral Blood Stem Cell Transplantation; Procedure: Bone Marrow Transplantation; Drug: Tacrolimus; Drug: My cophenolate Mofetil; Drug: Sirolimus; Biological: Granulocyte Colony-Stimulating Factor Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Leukemia | Myelodysplastic Syndrome | Prograf | Research | Stem Cell Therapy | Stem Cells | Tacrolimus | Transplants